Share This


Melasma is a hyperpigmentation disorder which has been the subject of intense research over the last 40 years. As yet no definitive therapeutic strategy has been demonstrated to eradicate it or to avoid relapse. The author provides an up to date review.


What is melasma?

Melasma is a depigmentation condition that effects the skin in areas exposed to the sun. The facial types are the most common and fall into three components; central facial, malar and mandibular. The central facial pattern is by far the most common. Although very rare, the extra facial forms are also described. The exact cause of melasma at molecular level remains largely unknown. However, the predisposing factors are well described and include sun exposure (UV), genetic and hormonal factors.

Aetiology and predisposing factors

UV exposure: The role of UV light as a predisposing factor to melasma has been consistently demonstrated both in clinical settings as well as in vitro [1]. Indeed UV light ability to generate oxygen free radicals and promote an increased production of melanin is thought to be a potential mechanism. This is supported by the fact that melasma patients are shown to have higher levels of oxidative stress markers than the control group [2]. Supporting that concept is the findings that skin areas stimulated by UV light are the site of an increased level of genes involved in melanogenis [3]. Furthermore, vascular endothelial growth factors (VEGF), which are produced by keratinocytes in response to UV damage, have been shown to promote the growth of human melanocytes in tissue culture [4]. The latter is believed to be one of the mechanisms of enhanced melanocyte activity in melasma. This has a direct practical clinical implication. Indeed, the role of protection against UV light has been consistently and clearly shown by many studies including two randomised control trials showing not only the prevention in melasma relapse [5] but also enhancing the efficacy of hydroquinone [6], a well-known inhibitor of melanin production.

Hormonal factors: Hormonal factors play a pivitol role in the production of melasma. This has been consistently supported by many studies correlating melasma with pregnancy, oral contraception or other hormonal therapies or conditions [7,8]. An in vitro comparative study of both epidermis and dermis have shown a significantly elevated progesterone receptors of the melasma skin when compared to the control [9]. However, the definitive role of hormones is not widely accepted and there appears to be no strong consensus about the exact role of hormonal factors. Indeed, in a large multicentre study performed in several countries looking at the role of UV and hormones in the development of melasma [10], the authors were only able to show 20% of the pregnancies were associated with melasma. The striking finding in this study was the highest risk factor in pregnant woman was correlated to greater outdoor activities; suggesting again a greater role of UV exposure. Thyroid dysfunction is also reported as a hormonal contributing factor. One study reported that patients with melasma have been found to be four times higher than the control group [11].


Strictly speaking, melasma is not an inherited disorder, although some family cases have been described. Nonetheless there is a genetic predisposition in darker skin types. Melasma effects mainly women, in particular women with darker skin.

Clinical relevance of the histological classification of melasma

Until recently the near dogmatic view was that melasma fell into three distinct histological types: epidermal, dermal and mixed. From that simple classification raised the consensus that establishing which type of melasma will define which treatment and furthermore even predict outcomes. Indeed, the dermal type has been consistently shown to be more difficult to treat with a higher rate of relapse.

In the epidermal type the melanin level is enhanced in all the layers of the epidermis, particularly the basal and suprabasilar layer. Morphologically the melanocytes as well as their dendrites and melanosomes are enlarged. In the dermal type melanin is found in the papillary dermis and is absorbed by macrophages. A wood light examination tool can easily determine the histological type. In the epidermal type, the hyperpigmentation is usually light brown. In a simplistic term, patients with epidermal hyperpigmentation are more prone to responding to depigmentation agents as the hyperpigmentation is more superficial. In the dermal type the appearance is more ashen or blue / grey in this case because the transport and elimination of pigment is performed by macrophages. The treatment is much less likely to respond to depigmentation agents. In the mixed type, the hyperpigmentation usually appears dark brown on the wood light examination.

Although this simple classification has been extremely helpful clinically, in more recent studies using sophisticated tools including electron microscopy, immunocytochemistry and in vivo confocal microscopy it clearly emerged that every melasma is actually of a mixed type, as melanin and melanophages are shown to be distributed in a non-homogenous fashion [12]. Therefore, it would appear that melasma is not solely an epidermal problem but in fact a complex pathology involving epidermal cells, keratinocytes, melanocytes, fibroblasts as well as vascular endothelial cells [12]. Areas with melasma are also shown to have a higher vascular network [12]. This concept is opening new research avenues with potential clinical implications.

Therapeutic strategies

There are four basic principles of managing melasma: photoprotection, topical, oral or interventional.


UV exposure is one of the main aetiological factors. Therefore, year round UV protection should be the absolute adjuvant to any other treatment. It is well documented that in the absence of sun exposure protection, systematic recurrence and relapse of melasma is systematic. The biochemical rationale in this crucial role of UV exposure has been summarised above (UV exposure).

Figure 1: Melanin production. Crucial role of tyrosinase inhibitors.



Hydroquinone (HQ): The currently available pharmacological therapies are based on the inhibition of the pivitol enzyme tyrosinase, which is the key enzyme in melanin production (Figure 1). Although different drugs have been used for more than four decades no definitive guidelines have been established to treat melasma. Although short-term results can be excellent, long-term can be frustrating as melasma has a tendency for relapse / reoccurrence. HQ is the most frequently used topical agent. It is a phenolic agent that inhibits tyrosinase enzyme responsible for the transformation of dopa to melanin (Figure 1). It is also believed that HQ reduces the melanocyte production. It could also act on the degradation of melanocytes and negatively influence the DNA and RNA synthesis inside the melanocytes [13]. The efficacy of HQ is directly proportional to the concentration. The currently accepted concentration in the UK is 4%. There is a consensus that above 4% the irritant properties become detrimental.

Retinoid: Retinoid reduces the melanin production through several pathways: firstly, it inhibits the transcription of tyrosinase. Secondly, when used in combination with HQ it reduces the oxidation of HQ, thereby improving or enhancing epidermal penetration. Several studies have supported the efficacy of retinoid in reducing, both subjectively and objectively, melasma pigmentation [14,15].

Corticosteroids: Although corticosteroids are known to reduce pigmentation through non selective pathways on the melanin production, and also known to have anti-inflammatory properties, they are not currently considered as a depigmenting drug as a monotherapy. There is an obvious concern regarding the well-known long-term side-effects on the skin including acne and telangiectasia [16,17]. The main interest of steroids is their role as an adjacent in combination therapies.

Azelaic acid: Azelaic acid is a tyrosinase inhibitor. It has the ability to destroy the abnormal melanocytes and reduce their proliferation.

Kojic Acid: Kojic acid is a fungal metabolite with a dual action as a tyrosinase inhibitor as well as a potent antioxidant. As a monotherapy it is much less effective than HQ. However, it has been shown to have a benefit as a dual therapy [15].

Combination therapies

The rationale of combination therapy is to improve the efficacy of a single agent but also to minimise the side-effects. Retinoid reduces the oxidation of HQ, thereby improving the penetration and leading to a lower concentration requirement. Steroids can significantly reduce the cutaneous irritant side-effects of other drugs. The original Klingmans formula described in 1975 includes HQ 5%, retinoid 0.1%, dexamethasone 0.1%. This initial formula has been altered by removing / adding or changing one or more of its components to suit individual skin requirements. The most common changes relate to the steroid component and the dosage. The concentration of retinoid and HQ has been reduced in more recent formulas. Combination therapies have been consistently shown to work quicker and more effectively than monotherapies because of thesynergistic effect [18,19].

Oral medications

The most commonly used oral compound is tranexamic acid (TXA). TXA is a synthetic compound of the amino acid lysine. It is a well-known agent in the field of surgery where it is used to treat coagulopathy. It has the ability to bind to the lysine binding site of the plasminogen protein hence it inhibits the plasminogen activator which ultimately inhibits the plasminogen to plasmin transformation. Plasminogen can also be found in the keratinocytes, as well as the basal epidermal cells. UV has the ability to stimulate the keratinocytes / plasminogen system. This results in the production of prostaglandin and Leukotrienes. These two compounds are known to stimulate the production of melanin. It is the TXA ability to bind to plasminogen that will inhibit the melanogenesis.

Another mechanism of TXA may involve the inhibition of vascular endothelium growth factors and endothelin 1 which are known to increase the vascular network [20]. This is important in light of the new concept regarding the histological classification described above [12]. Although TXA has the ability to act on both melanogenis as well as the surrounding cells, it is not devoid from complications [21].

The efficacy of TXA and melasma has been widely studied. In two randomised controlled trials, TXA in combination with topical retinoid, topical HQ and steroids displayed a quicker response with longevity compared to the control group [22,23].

Interventional procedures

Interventional therapies described to treat melasma include laser therapy for pigmentation and for reducing the vascular network, chemical peels, microdermabrasion and microneedling. These procedures are usually associated with other therapeutic modalities such as topical therapies. Most studies support an additional beneficial effect when combined with topical therapies. Laser therapy for melasma remains challenging, particularly in patients with darker skin types. In this particular group, which is known to be at a higher risk of melasma, laser therapy can generate side-effects. Indeed, the darker skin has larger and non-aggregated melanosomes [24]. This higher concentration of melanin has the ability to absorb laser energy more diffusely and therefore trigger thermal lesions within the adjacent tissues. This can result in side-effects such as post inflammatory pigmentation and / or scarring. In addition, the melanin surrounding the area with melasma can act as a competitor (by absorbing the energy intended for melasma hence decreasing the efficacy).

For all these reasons, new generations of lasers have been developed. Recent studies have demonstrated safety and efficacy of fractional picosecond laser for treatment of melasma [25,26,27]. These studies showed a clear benefit of the laser as an combined treatment with HQ or as a monotherapy in dark skin. However, the lack of long-term follow-up and the small sample studies does not allow any solid conclusions to be drawn.

“Despite 42 years of experience in managing melasma and the existence of multiple pharmacological and interventional therapeutic tools, there is currently no definitive treatment to eradicate melasma or to prevent its relapse”


Conclusion and future clinical research prospects

Despite 42 years of experience in managing melasma and the existence of multiple pharmacological and interventional therapeutic tools, there is currently no definitive treatment to eradicate melasma or to prevent its relapse. This frustrating aspect must be included in the consent form.

Nevertheless, new knowledge and understanding are emerging at molecular and histological level. This supports the notion that melasma is multifactorial in its aetiology and does not fall into three simple categories. One should revisit therapies that will manage all of the complex aetiology particularly targeting the complex interplay between melanocytes, keratinocytes, fibroblasts, vascular endothelial cells, as well as molecules recreated by these cells.



1. Duteil L, Cardot‐Leccia N, Queille‐Roussel C, et al. Differences in visible light‐induced pigmentation according to wavelengths: a clinical and histological study in comparison with UVB exposure. Pigment Cell Melanoma Res 2014;27(5):2-826.
2. Jo HY, Kim CK, Suh IB, et al. Co‐localization of inducible nitric oxide synthase and phosphorylated Akt in the lesional skins of patients with melasma. J Dermatol 2009;36(1):10-6.
3. Kang HY, Suzuki I, Lee DJ, et al. Transcriptional profiling shows altered expression of wnt pathway–and lipid metabolism–related genes as well as melanogenesis-related genes in melasma. J Invest Dermatol 2011;131(8):1692-700.
4. Kim EJ, Park HY, Yaar M, Gilchrest BA. Modulation of vascular endothelial growth factor receptors in melanocytes. Exp Dermatol 2005;14(8):625-33.
5. Boukari F, Jourdan E, Fontas E, et al. Prevention of melasma relapses with sunscreen combining protection against UV and short wavelengths of visible light: a prospective randomized comparative trial. J Am Acad Dermatol 2015;72(1):189-90.
6. Castanedo‐Cazares JP, Hernandez‐Blanco D, Carlos‐Ortega B, et al. Near‐visible light and UV photoprotection in the treatment of melasma: a double‐blind randomized trial. Photodermatol Photoimmunol Photomed 2014;30(1):35-42.
7. Guinot C, Cheffai S, Latreille J, et al. Aggravating factors for melasma: a prospective study in 197 Tunisian patients. J Eur Acad Dermatol Venereol 2010;24(9):1060‑9.
8. Handel AC, Miot LDB, Miot HA. Melasma: a clinical and epidemiological review. Anais Brasileiros de Dermatologia 2014;89(5):771-82.
9. Jang YH, Lee JY, Kang HY, et al. Oestrogen and progesterone receptor expression in melasma: an immunohistochemical analysis. J Eur Acad Dermatol Venereol 2010;24(11):1312-6.
10. Ortonne JP, Arellano I, Berneburg M, et al. A global survey of the role of ultraviolet radiation and hormonal influences in the development of melasma. J Eur Acad Dermal Venereol 2009;23:1254-62.
11. Lutfi RJ, Fridmanis M, Misiunas AL, et al. Association of melasma with thyroid autoimmunity and other thyroidal abnormalities and their relationship to the origin of the melasma. J Clin Endocrinol Metab 1985;61(1):28-31.
12. Kwon SH, Hwang YJ, Lee SK, Park KC. Heterogeneous pathology of melasma and its clinical implications. Int J Mol Sc 2016;17(6):824.
13. Palumbo A, d’Ischia M, Misuraca G, Prota G. Mechanism of inhibition of melanogenesis by hydroquinone. Biochim Biophys Acta Gen Subj 1991;1073(1):85-90.
14. Griffiths CEM, Finkel LJ, Ditre CM, et al. Topical tretinoin (retinoic acid) improves melasma. A vehicle‐controlled, clinical trial. Brit J Dermatol 1993;129(4):415-21.
15. Lee J, Jung E, Lee J, et al. Mechanisms of melanogenesis inhibition by 2, 5‐dimethyl‐4‐hydroxy‐3 (2H)‐furanone. Brit J Dermatol 2007;157(2):242-248.
16. Gupta AK, Gover MD, Nouri K, Taylor S. The treatment of melasma: a review of clinical trials. J Am Acad Dermatol 2006;55(6):1048-65.
17. Deo KS, Dash KN, Sharma YK, et al. Kojic acid vis-a-vis its combinations with hydroquinone and betamethasone valerate in melasma: a randomized, single blind, comparative study of efficacy and safety. Indian J Dermatol 2013;58(4):281.
18. Rajaratnam R, Halpern, J, Salim A, Emmett C. Interventions for melasma. Cochrane Database Syst Rev 2010;7(7):CD003583.
19. Gong Z, Lai W, Zhao G, et al. Efficacy and safety of fluocinolone acetonide, hydroquinone, and tretinoin cream in Chinese patients with melasma: A randomized, double-blind, placebo-controlled, multicenter, parallel-group study. Clin Drug Investig 2015;35(6):385-95.
20. Kim SJ, Park JY, Shibata T, et al. Efficacy and possible mechanisms of topical tranexamic acid in melasma. Clinical Exp Dermatol 2016;41(5):480-5.
21. Lee HC, Thng TGS, Goh CL Oral tranexamic acid (TA) in the treatment of melasma: a retrospective analysis. J Am Acad Dermatol 2016;75(2):385-92.
22. Padhi T and Pradhan S Oral tranexamic acid with fluocinolone-based triple combination cream versus fluocinolone-based triple combination cream alone in melasma: an open labeled randomized comparative trial. Indian J Dermatol 2015;60(5):520.
23. Del Rosario E, Florez-Pollack S, Zapata Jr L, et al. Randomized, placebo-controlled, double-blind study of oral tranexamic acid in the treatment of moderate-to-severe melasma. J Am Acad Dermatol 2018;78(2):363-9.
24. Smit, NP, Kolb RM, Lentjes EGWM, et al. Variations in melanin formation by cultured melanocytes from different skin types. Arch Dermatol Res 1998;290(6):342‑9.
25. Chalermchai T, Rummaneethorn P. Effects of a fractional picosecond 1064 nm laser for the treatment of dermal and mixed type melasma. J Cosmet Laser Ther 2018;20(3):134-9.
26. Kung KY, Shek SYN, Yeung CK, Chan HHL Evaluation of the safety and efficacy of the dual wavelength picosecond laser for the treatment of benign pigmented lesions in Asians. Lasers Surg Med 2019;51(1):14-22.
27. Choi YJ, Nam JH, Kim JY, et al. Efficacy and safety of a novel picosecond laser using combination of 1064 and 595 nm on patients with melasma: A prospective, randomized, multicenter, split‐face, 2% hydroquinone cream‐controlled clinical trial. Lasers Surg Med 2017;49(10):899-907.




Share This
Clare Amrani

Iuvenis Aesthetics, Harrow on the Hill, UK.

View Full Profile